Microclima e produção de videiras 'Niágara rosada' em cultivo orgânico sob cobertura plástica.

O uso de coberturas plásticas sobre vinhedos tem aumentado no Sul do Brasil, visando a atenuar limitações climáticas. Este estudo objetivou quantificar alterações micrometeorológicas causadas por cobertura plástica e seus efeitos no desenvolvimento e na produção de videiras ?Niágara Rosada?, em cultivo orgânico. O estudo foi realizado em Bento Gonçalves-RS, num vinhedo conduzido em sistema latada e submetido a dois ambientes: em céu aberto e coberto por plástico transparente (160μm) em arcos descontínuos. Nos dois ambientes, foram monitoradas radiação fotossinteticamente ativa (RFA) e temperatura do ar. Avaliaram-se fenologia, índice de área foliar (IAF), peso e diâmetro de bagas, teor de sólidos solúveis e acidez total titulável, incidência de doenças fúngicas e rendimento. A cobertura reduziu em um terço a RFA incidente (-34%) e aumentou as temperaturas máximas do ar (+3,1ºC). Ela acelerou o ciclo vegetativo das videiras até a maturação, mas retardou a queda de folhas. A cobertura promoveu incrementos de IAF, duração da área foliar e produção de uvas, de 12,3 para 27,1 t ha-1. Não foi observada incidência de doenças fúngicas no vinhedo coberto. Portanto, a cobertura plástica sobre vinhedos é uma alternativa importante na produção de uvas de mesa no Sul do Brasil, em cultivo orgânico

Safety and efficacy of fenproporex for obesity treatment: a systematic review

ABSTRACT OBJECTIVE To evaluate clinical evidence on the safety and efficacy of fenproporex for treating obesity. METHODS MEDLINE, LILACS and Cochrane Controlled Trials Register were searched as well as references cited by articles and relevant documents. Two authors independently assessed the studies for inclusion and regarding risk of bias, collected data, and accuracy. Eligible studies were all those placebo-controlled that provided data on the efficacy and safety of Fenproporex to treat obesity. RESULTS Only four controlled studies met the inclusion criteria. One randomized, placebo-controlled trial on Fenproporex was found on electronic databases. Three placebo-controlled studies (in non-indexed journals) were identified by hand-searching. Patients with cardiovascular and other comorbidities were excluded in all studies. Trials lasted from 40 to 364 days and doses ranged from 20 to 33.6 mg/d. All controlled studies found that weight loss among Fenproporex-treated patients was greater than that produced by the placebo, but drug effect was modest. Fenproporex produced additional weight reductions of 4.7 kg (one year), 3.8 kg (six months) and 1.55 kg (two months) in average, in relation to diet and exercise only (three trials). Insomnia, irritability, and anxiety were the most frequently reported side effects in the four studies. CONCLUSIONS There is a paucity of randomized, placebo-controlled trials on Fenproporex and those identified here present major methodological flaws. These studies suggest that Fenproporex is modestly effective in promoting weight loss. Nonetheless, they failed to provide evidence that it reduces obesity-associated morbidity and mortality. Data from these studies are insufficient to determine the risk-benefit profile of Fenproporex. Abuse potential and amphetamine-like adverse effects are causes for concern